Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics

Michael Maes, Luisella Bocchio Chiavetto, Stefano Bignotti, Giani Jean Battisa Tura, Rosaria Pioli, Francesco Boin, Gunter Kenis, Eugene Bosmans, Raf De Jongh, Aihua Lin, Giorgio Racagni, C. A. Altamura

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

There is now some evidence that schizophrenia may be accompanied by an activation of the inflammatory response system (IRS) and that typical antipsychotics may suppress some signs of IRS activation in that illness. This study was carried out to examine (i) the serum concentrations of interleukin-6 (IL-6), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA) and Clara Cell protein (CC16), an endogenous anticytokine, in nonresponders to treatment with typical neuroleptics and (ii) the effects of atypical antipsychotics on the above IRS variables. The above parameters were determined in 17 patients with treatment-resistant schizophrenia (TRS) to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. Patients with TRS had repeated measurements of the IRS variables before and 2 and 4 months after treatment with atypical antipsychotics. Serum IL-6 was significantly higher in schizophrenic patients, irrespective of their response to typical antipsychotics, than in normal controls. Serum IL-1RA was significantly higher in the TRS patients than in controls, whereas responders took up an intermediate position. The serum concentrations of CC16 were significantly lower after treatment with atypical antipsychotics during 4 months than before treatment. It is concluded that (i) schizophrenia and, in particular, TRS is characterized by an activation of the monocytic arm of cell-mediated immunity and (ii) atypical antipsychotics may decrease the anti-inflammatory capacity of the serum in TRS patients. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalEuropean Neuropsychopharmacology
Volume10
Issue number2
Publication statusPublished - Mar 2000

Fingerprint

Antipsychotic Agents
Schizophrenia
Therapeutics
Serum
Interleukin-6
Interleukin-6 Receptors
Cellular Immunity
Immunity
Healthy Volunteers
Anti-Inflammatory Agents

Keywords

  • CC16
  • Clozapine
  • Cytokines
  • Interleukin-6
  • Schizophrenia
  • Treatment resistance

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. / Maes, Michael; Bocchio Chiavetto, Luisella; Bignotti, Stefano; Battisa Tura, Giani Jean; Pioli, Rosaria; Boin, Francesco; Kenis, Gunter; Bosmans, Eugene; De Jongh, Raf; Lin, Aihua; Racagni, Giorgio; Altamura, C. A.

In: European Neuropsychopharmacology, Vol. 10, No. 2, 03.2000, p. 119-124.

Research output: Contribution to journalArticle

Maes, M, Bocchio Chiavetto, L, Bignotti, S, Battisa Tura, GJ, Pioli, R, Boin, F, Kenis, G, Bosmans, E, De Jongh, R, Lin, A, Racagni, G & Altamura, CA 2000, 'Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics', European Neuropsychopharmacology, vol. 10, no. 2, pp. 119-124.
Maes, Michael ; Bocchio Chiavetto, Luisella ; Bignotti, Stefano ; Battisa Tura, Giani Jean ; Pioli, Rosaria ; Boin, Francesco ; Kenis, Gunter ; Bosmans, Eugene ; De Jongh, Raf ; Lin, Aihua ; Racagni, Giorgio ; Altamura, C. A. / Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. In: European Neuropsychopharmacology. 2000 ; Vol. 10, No. 2. pp. 119-124.
@article{3574fb46b5fa45caa80de5853d50f41b,
title = "Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics",
abstract = "There is now some evidence that schizophrenia may be accompanied by an activation of the inflammatory response system (IRS) and that typical antipsychotics may suppress some signs of IRS activation in that illness. This study was carried out to examine (i) the serum concentrations of interleukin-6 (IL-6), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA) and Clara Cell protein (CC16), an endogenous anticytokine, in nonresponders to treatment with typical neuroleptics and (ii) the effects of atypical antipsychotics on the above IRS variables. The above parameters were determined in 17 patients with treatment-resistant schizophrenia (TRS) to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. Patients with TRS had repeated measurements of the IRS variables before and 2 and 4 months after treatment with atypical antipsychotics. Serum IL-6 was significantly higher in schizophrenic patients, irrespective of their response to typical antipsychotics, than in normal controls. Serum IL-1RA was significantly higher in the TRS patients than in controls, whereas responders took up an intermediate position. The serum concentrations of CC16 were significantly lower after treatment with atypical antipsychotics during 4 months than before treatment. It is concluded that (i) schizophrenia and, in particular, TRS is characterized by an activation of the monocytic arm of cell-mediated immunity and (ii) atypical antipsychotics may decrease the anti-inflammatory capacity of the serum in TRS patients. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "CC16, Clozapine, Cytokines, Interleukin-6, Schizophrenia, Treatment resistance",
author = "Michael Maes and {Bocchio Chiavetto}, Luisella and Stefano Bignotti and {Battisa Tura}, {Giani Jean} and Rosaria Pioli and Francesco Boin and Gunter Kenis and Eugene Bosmans and {De Jongh}, Raf and Aihua Lin and Giorgio Racagni and Altamura, {C. A.}",
year = "2000",
month = "3",
language = "English",
volume = "10",
pages = "119--124",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "2",

}

TY - JOUR

T1 - Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics

AU - Maes, Michael

AU - Bocchio Chiavetto, Luisella

AU - Bignotti, Stefano

AU - Battisa Tura, Giani Jean

AU - Pioli, Rosaria

AU - Boin, Francesco

AU - Kenis, Gunter

AU - Bosmans, Eugene

AU - De Jongh, Raf

AU - Lin, Aihua

AU - Racagni, Giorgio

AU - Altamura, C. A.

PY - 2000/3

Y1 - 2000/3

N2 - There is now some evidence that schizophrenia may be accompanied by an activation of the inflammatory response system (IRS) and that typical antipsychotics may suppress some signs of IRS activation in that illness. This study was carried out to examine (i) the serum concentrations of interleukin-6 (IL-6), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA) and Clara Cell protein (CC16), an endogenous anticytokine, in nonresponders to treatment with typical neuroleptics and (ii) the effects of atypical antipsychotics on the above IRS variables. The above parameters were determined in 17 patients with treatment-resistant schizophrenia (TRS) to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. Patients with TRS had repeated measurements of the IRS variables before and 2 and 4 months after treatment with atypical antipsychotics. Serum IL-6 was significantly higher in schizophrenic patients, irrespective of their response to typical antipsychotics, than in normal controls. Serum IL-1RA was significantly higher in the TRS patients than in controls, whereas responders took up an intermediate position. The serum concentrations of CC16 were significantly lower after treatment with atypical antipsychotics during 4 months than before treatment. It is concluded that (i) schizophrenia and, in particular, TRS is characterized by an activation of the monocytic arm of cell-mediated immunity and (ii) atypical antipsychotics may decrease the anti-inflammatory capacity of the serum in TRS patients. Copyright (C) 2000 Elsevier Science B.V.

AB - There is now some evidence that schizophrenia may be accompanied by an activation of the inflammatory response system (IRS) and that typical antipsychotics may suppress some signs of IRS activation in that illness. This study was carried out to examine (i) the serum concentrations of interleukin-6 (IL-6), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA) and Clara Cell protein (CC16), an endogenous anticytokine, in nonresponders to treatment with typical neuroleptics and (ii) the effects of atypical antipsychotics on the above IRS variables. The above parameters were determined in 17 patients with treatment-resistant schizophrenia (TRS) to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. Patients with TRS had repeated measurements of the IRS variables before and 2 and 4 months after treatment with atypical antipsychotics. Serum IL-6 was significantly higher in schizophrenic patients, irrespective of their response to typical antipsychotics, than in normal controls. Serum IL-1RA was significantly higher in the TRS patients than in controls, whereas responders took up an intermediate position. The serum concentrations of CC16 were significantly lower after treatment with atypical antipsychotics during 4 months than before treatment. It is concluded that (i) schizophrenia and, in particular, TRS is characterized by an activation of the monocytic arm of cell-mediated immunity and (ii) atypical antipsychotics may decrease the anti-inflammatory capacity of the serum in TRS patients. Copyright (C) 2000 Elsevier Science B.V.

KW - CC16

KW - Clozapine

KW - Cytokines

KW - Interleukin-6

KW - Schizophrenia

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=17744415696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744415696&partnerID=8YFLogxK

M3 - Article

C2 - 10706993

AN - SCOPUS:17744415696

VL - 10

SP - 119

EP - 124

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 2

ER -